A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients

NCT04736394 | Unknown Phase 3 DMC FDA Drug

• 1 other identifier: YHCT-NIT-R2
• Study Type: interventional
• Target: 800
• Locations: 1 country
• Sites: 1

Brief Summary

A multi-center, randomized, open-label, parallel-controlled Phase Ⅲ clinical trial to evaluate the clinical safety and efficacy of APL-1202 as a single-agent oral treatment versus intravesical instillation of Epirubicin hydrochloride in naïve intermediate-risk non-muscle invasive bladder cancer (NMIBC) patients

Conditions

Non-muscle Invasive Bladder Cancer

Outcome Measures

Primary Outcomes (1)

• Event-free survival (EFS)

  Event-free survival (EFS) based on the assessment of pathological report from the Independent Pathology Review Committee (IPRC)

  Up to 48 months

Secondary Outcomes (7)

• Event-free survival (EFS) based on the assessment of pathological report from each site

  Up to 48 months

• Overall survival (OS)

  Up to 48 months

• Recurrence-free rate

  Up to 48 months

• Progression-free rate

  Up to 48 months

• Clinical benefit rates

  Up to 48 months

Other Outcomes (1)

• Cystectomy-free survival (CFS)

  Up to 48 months

Study Arms (2)

Epirubicin hydrochloride group

ACTIVE COMPARATOR

intravesical instillation of Epirubicin hydrochloride

Drug: Epirubicin Hydrochloride

APL-1202 group

EXPERIMENTAL

receive APL-1202 single-agent oral treatment

Drug: APL-1202

Interventions

APL-1202 DRUG

APL-1202 single-agent oral treatment

APL-1202 group

Epirubicin Hydrochloride DRUG

Epirubicin hydrochloride

Epirubicin hydrochloride group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• All patients must meet all the following criteria:
• Must be informed of the investigational nature of this study and must provide written informed consent
• Age ≥18 years, male or female
• Non-muscle invasive transitional cell carcinoma of the bladder is histologically confirmed by Independent Pathology Review Committee (IPRC). Diagnosis and classification of intermediate-risk NMIBC is according to 2014 CUA Guideline of Diagnosis and Treatment of Urological Diseases in China:
• Low-risk: Primary, solitary, TaGl (PUNLMP, low-grade urothelial carcinoma), \<3cm, no CIS. (Note: the above conditions must be met at the same time as a low-risk NMIBC) Intermediate-risk: All tumours not defined in the two adjacent categories (between the category of low and high risk) High-risk: Any of the following: ① T1 tumour; ②G3(high-grade urothelial carcinoma) tumour;③carcinoma in situ (CIS); ④ Multiple, recurrent and large (\> 3 cm) TaG1G2(low-grade urothelial carcinoma) tumours (all features must be present)
• No visible tumor after transurethral resection of bladder tumor (TURBT) on tumor lesion. Some requirements about Re-TURBT are as follows: It is recommended to conduct the secondary TURBT under following situations: incomplete first TURBT; no muscle tissue found in the first TURBT specimen, except Ta G1 (low grade) tumor and CIS only.
• The secondary TURBT is recommended 2-6 weeks, but better at 4 weeks, after the first TURBT.
• For subjects undergoing secondary TURBT, they will be enrolled after the second TURBT
• Subjects who never received intravesical instillation (including BCG or intravesical chemotherapy) prior to enrollment, except single, immediate, post-operative intravesical chemotherapy.
• Willing to provide pathological tissue specimen for assessment
• ECOG PS ≤ 1
• Patients, who have not received blood transfusion or colony-stimulating factor treatment within 14 days before the examination, must have normal organ and marrow function within 42 days of study entry (according to normal range in clinical site).
• Absolute neutrophil count \>1.5×109/L Platelets \> 100 ×109/L Hemoglobin \> 9.0 g/dL Alkaline phosphatase \< 2.5 ULN GFR (Cockcroft-Gault formula calculated) ≥ 50 mL/min Total bilirubin, alanine aminotransferase or aspartate aminotransferase\< 1.5 ULN INR \<1.5, except for subjects receiving anticoagulation therapy
• Female should be either surgically sterilized or menopause or agree to use effective contraceptive measures during treatment. Women of reproductive age must have a negative result of pregnancy test during the screening period (pregnancy test will be not required if one of the following situations exists: the subject has undergone sterilization such as hysterectomy and/or bilateral oophorectomy, has no menstruation for 12 months and been diagnosed as menopause based on factors such as age). However, pregnancy tests are required for patients with bilateral fallopian tube ligation.
• Male subjects should be either surgically sterilized or agreed to use effective contraceptive measures. From signing the informed consent, subjects must take continuous measures until 3 months after the end of the treatment of trial. The definition of effective contraceptive measures will be based on the principal investigator(PI) or appointed delegate.

You may not qualify if:

• The presence of any of the following will exclude a patient from study enrollment:
• Low-risk: Primary, solitary, TaGl (PUNLMP, low-grade urothelial carcinoma), \<3cm, no CIS. (PS: the above conditions must be met at the same time as a low-risk NMIBC)
• High-risk: Any of the following: ① T1 tumour; ②G3(high-grade urothelial carcinoma) tumour;③carcinoma in situ (CIS); ④ Multiple, recurrent and large (\> 3 cm) TaG1G2(low-grade urothelial carcinoma) tumours (all features must be present)
• Tumors of T2 stage or more serious
• The histological types are mainly non-urothelial carcinomas such as squamous cell carcinoma and adenocarcinoma
• Urothelial carcinoma outside the bladder (renal pelvis, ureter or urethra)
• Received intravesical therapy in last TURBT/cystoscopy prior to treatment period, but not including immediate intravesical therapy once (the subjects who received the immediate intravesical therapy need to be recorded in e-CRF)
• Received surgery (not includes TURBT/cystoscopy), radiation therapy, or systemic therapy within 6 weeks before enrollment
• Malignancies within 2 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in-situ' of the cervix
• Grade 3 (according to the NCI CTCAE 5.0) hemorrhage in any part of body within 6 weeks before starting the treatment of trial
• Any of the following within 6 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism
• Hypertension that cannot be controlled by medications (systolic blood pressure≥140 mmHg and/or diastolic blood pressure≥90mmHg)
• Uncontrolled active infections before starting the treatment of trial, such as acute pneumonia, active hepatitis B, etc.
• Dysphagia or known drug absorption disorders
• Anuria

Sponsors & Collaborators

• Jiangsu Yahong Meditech Co., Ltd aka Asieris: lead

Study Sites (1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 201203, China

RECRUITING

MeSH Terms

Conditions

Non-Muscle Invasive Bladder Neoplasms

Interventions

Epirubicin

Condition Hierarchy (Ancestors)

Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Urinary Bladder Diseases; Urologic Diseases; Male Urogenital Diseases

Intervention Hierarchy (Ancestors)

Doxorubicin; Daunorubicin; Anthracyclines; Naphthacenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Polycyclic Compounds; Aminoglycosides; Glycosides; Carbohydrates

Central Study Contacts

Mingming Zhang, MD

CONTACT

8613816002336; mmzhang@asieris.cn

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 29, 2021
• First Posted: February 3, 2021
• Study Start: September 29, 2021
• Primary Completion: March 1, 2025
• Study Completion: December 31, 2025
• Last Updated: February 22, 2022

Record last verified: 2022-02

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)